Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension

The development of parenteral prostacyclin therapy marked a dramatic breakthrough in the treatment of pulmonary arterial hypertension (PAH). Intravenous (IV) epoprostenol was the first PAH specific therapy and to date, remains the only treatment to demonstrate a mortality benefit. Because of the inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugliese, Steven C, Bull, Todd M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734815/
https://www.ncbi.nlm.nih.gov/pubmed/26869810
http://dx.doi.org/10.2147/IBPC.S68230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734815/
https://www.ncbi.nlm.nih.gov/pubmed/26869810
http://dx.doi.org/10.2147/IBPC.S68230

Ejemplares similares